Revised guidelines for the prevention of future stroke for survivors of a stroke or transient ischemic attack (TIA) align with other guidelines and provide additional sections based on new insights on risk factors.

When Medtronic announced in January that SYMPLICITY HTN-3 failed to meet its efficacy endpoint, it sounded like the beginning of the end for renal denervation as a treatment for uncontrolled hypertension.

ZZ Biotech today announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke.

A pre-post analysis of a national stroke initiative found patients were more likely to receive timely treatment and have better outcomes after the launch of the quality improvement program. The results were published in the April 23/30 issue of JAMA.

The Endurant AAA stent graft system from Medtronic, Inc. continues to demonstrate exceptional long-term performance in the endovascular treatment of abdominal aortic aneurysms, according to new clinical data presented for the first time at the 2014 Charing Cross international symposium in London.

GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque(tm) (iodixanol) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue(r) (iopamidol) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology's 63rd Annual Scientific Session and Expo.

Covidien is recalling some endovascular devices due to a coating defect.

The European Society of Hypertension (ESH) is calling for rigorous trials on renal denervation as a therapy for patients with treatment-resistant hypertension in the wake of results presented in the failed SYMPLICITY HTN-3 clinical trial.